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ABSTRACT 
Glucocorticoid binding to the intracellular glucocorticoid receptor (GR) stimulates the 
translocation of the GR from the cytosol to the nucleus, which leads to the transactivation or 
transrepression of gene transcription.  However, multiple lines of evidence suggest that 
glucocorticoid signaling can also be initiated from the plasma membrane.  Here, we provide 
evidence for membrane-initiated glucocorticoid signaling by a membrane-impermeant 
dexamethasone-bovine serum albumin (Dex-BSA) conjugate, which induced GR nuclear 
trafficking in hypothalamic neurons in vitro and in vivo. The GR nuclear translocation induced by 
a membrane-impermeant glucocorticoid suggests trafficking of an unliganded GR. The 
membrane-initiated GR trafficking was not blocked by inhibiting ERK MAPK, p38 MAPK, PKA, 
Akt, Src kinase, or calcium signaling, but was inhibited by Akt activation.  Short-term exposure 
of hypothalamic neurons to dexamethasone (Dex) activated the glucocorticoid response 
element (GRE), suggesting transcriptional transactivation, whereas exposure to the Dex-BSA 
conjugate failed to activate the GRE, suggesting differential transcriptional activity of the 
liganded compared to the unliganded GR.  Microarray analysis revealed divergent 
transcriptional regulation by Dex-BSA compared to Dex. Together, our data suggest that 
signaling from a putative membrane glucocorticoid receptor induces the trafficking of unliganded 
GR to the nucleus, which elicits a pattern of gene transcription that differs from that of the 
liganded receptor. The differential transcriptional signaling by liganded and unliganded 
receptors may contribute to the broad range of genetic regulation by glucocorticoids, and may 
help explain some of the different off-target actions of glucocorticoid drugs. 
 
 
Keywords: glucocorticoid receptor, hypothalamus, membrane signaling, nuclear 
translocation, genomic, nongenomic  
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INTRODUCTION 
Canonical glucocorticoid transcriptional regulation is mediated by glucocorticoid binding 
to the intracellular glucocorticoid receptor (GR), translocation of the liganded GR complex to the 
nucleus, and binding of the GR to the glucocorticoid response element (GRE) or to other 
transcription factors [1].  Trafficking of the GR from the cytosol to the nucleus is the first step, 
following glucocorticoid binding, in the transcriptional regulatory cascade of the activated GR, 
and occurs within minutes of ligand binding [2].  In the absence of steroid, the unliganded GR is 
bound to chaperone proteins as part of a complex that is transcriptionally inactive. However, an 
equilibrium exists between the cytosolic and nuclear GR in the absence of ligand [3], indicating 
that shuttling of the GR between the cytosol and nucleus occurs in the absence of steroid, 
although the signal(s) that stimulate(s) the trafficking of unliganded GR and the transcriptional 
functionality of the unliganded GR are not well understood.   
  A GRα isoform, GRα-D, is expressed in neurons at varying levels at different 
developmental stages [4], and can be found in the nucleus of glucocorticoid-free cells and 
associated with GRE-containing promoters in the absence of glucocorticoid [5].  Although the 
cellular actions of unliganded GR in the nucleus are not fully understood, there is evidence from 
a mouse mammary cell line that unliganded GR is capable of both negatively and positively 
regulating gene transcription [6].  Some cellular conditions can induce nuclear localization of the 
unliganded GR, including heat shock [7] and shear stress [8].  Under shear stress conditions, 
such as those experienced by aortic endothelial cells, the unliganded GR has been reported to 
regulate gene transcription [8].   
The rapid actions of glucocorticoids range from the production of endocannabinoid as a 
retrograde messenger [9], to regulation of ion channels [10,11], to inhibitory effects on immune 
cells [12–14]. Many different kinase signaling pathways have been implicated in the rapid 
actions of glucocorticoids mediated by putative membrane glucocorticoid receptors, including 
ERK-MAPK [9], SRC [15], protein kinase A [9,16,17], and protein kinase C [18]. 
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Here, we compared the membrane-impermeant glucocorticoid conjugate, 
dexamethasone-bovine serum albumin (Dex-BSA) with the membrane-permeant synthetic 
glucocorticoid dexamethasone (Dex) in its capacity to stimulate the nuclear translocation of GR 
and to induce transcriptional activity in hypothalamic cells in vitro and in vivo. We analyzed the 
Dex-BSA conjugate for its stability and purity in solution in a companion paper (Weiss et al., 
2017).  
 
EXPERIMENTAL 
Cell Cultures: 
mHypoE-N42 cell line (Cellutions Biosystems): Immortalized hypothalamic mHypoE-N42 (N42) 
cells [20] were plated at a density of  4.5 x 104 cells/well in 24-well plates (CORNING) 
containing 12 mm glass coverslips, size 0 (Carolina Biological, Burlington, NC), or in 96-well 
plates (Falcon, Tewksbury, MA) in 1X Dulbecco’s Modified Eagle Medium (DMEM, MediaTech, 
Manassas, VA) with 1% Antibiotic Antimycotic Solution and 0.2% Plasmocin Prophylactic® (to 
protect against mycoplasma contamination, Invivogen, San Diego, CA) (N42 medium) 
supplemented with  5% fetal bovine serum (FBS, Atlas Biologicals) .  Plates were incubated at 
37˚C with 5% CO2 until approximately 80% confluent.  The N42 medium was then removed, 
cells were washed once with 1X D-phosphate buffered saline (PBS), and fresh N42 medium 
supplemented with 5% charcoal-stripped (CS) FBS was added for 16 hours at 37˚C with 5% 
CO2 to ensure the removal of all exogenous hormones. 
 
Primary Hypothalamic Cell Culture: Hypothalami were dissected from at least 5 male mouse 
pups (C57BL/6:129) on postnatal day 1 and placed in ice-cold sterile 1X Hanks’ Buffered Salt 
Solution (HBSS) (GIBCO®, Pittsburgh, PA). Males were used to match our previous 
electrophysiological studies on rapid glucocorticoid actions in hypothalamic neurons.  The tissue 
was digested in 3 ml of 1X 0.25% trypsin with 2.21 mM EDTA (CORNING, Manassas, VA) at 
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37˚C for 15 minutes with gentle shaking.  Neurobasal A (Invitrogen, Grand Island, NY) + 1% 
Glutamax (Invitrogen) supplemented with 2% B27 (Invitrogen), 5% FBS and 1% Antibiotic 
Antimycotic Solution (CORNING) (complete Neurobasal medium) was added.  Cells were 
triturated with a series of three progressively smaller diameter fire-polished Pasteur pipets 
(Fisher Scientific, Pittsburgh, PA) until fully suspended. Supernatant was plated on poly-D-
lysine-coated 12 mm glass coverslips, size 0, in 24-well plates or in PDL-coated 96-well plates 
and kept at 37˚C with 5% CO2 overnight in complete Neurobasal medium plus 33% 1X DMEM 
with 5% FBS.  Medium was removed and replaced at 2 days in vitro (DIV) with fresh complete 
Neurobasal medium, and cells were maintained at 37˚C with 5% CO2 for 7 DIV.  Half of the 
medium was removed and replaced with fresh complete Neurobasal medium every other day. 6 
hours prior to hormone treatment, the medium was replaced with Neurobasal A supplemented 
with 1% Glutamax only. 
 
Hormone Treatments: Inhibitors or activators were added to the media either 15 minutes prior 
to a 20-minute hormone treatment or 30 minutes prior to a 60-minute hormone treatment at 
37˚C with 5% CO2.  All hormones and drugs were dissolved in dimethyl sulfoxide (DMSO) 
except for Dex-BSA (Steraloids, Newport, RI), which was dissolved in sterile water with 25% 
cyclodextrin (Sigma-Aldrich, St. Louis, MO) as a carrier to increase solubility. Dex and Dex-BSA 
were used at concentrations of 1 µM and 100 nM, respectively, unless otherwise stated. The 
Dex-BSA had a steroid-to-BSA molar ratio of 37:1. The number of Dex molecules in the Dex-
BSA conjugate that are available for binding to a membrane receptor is unknown. We assumed 
that multiple Dex molecules per BSA were available for binding the membrane receptors. We 
selected the lowest effective concentration of Dex-BSA and used a 10-fold higher concentration 
of Dex for comparison. We determined empirically that the two compounds were of 
approximately equal efficacy (Fig. 1). For the filtrate experiments, Dex-BSA was dissolved in 
water at a stock concentration of 100 µM, then added to 5% charcoal-stripped DMEM with 5% 
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CS FBS at 37°C for 20 minutes.  The culture media was then filtered through a 10 kD Amicon 
filter (Millipore) at room temperature for 10 minutes at 14,000 rcf to obtain the Dex-BSA filtrate, 
which contained anything present in the Dex-BSA-treated media with a molecular weight <10 
kD.   
 
Immunocytochemistry: Cells were fixed in 4% paraformaldehyde (Sigma-Aldrich) for 15 
minutes at room temperature.  The fixative was removed and cells were washed in 1X D-PBS 
and then incubated in 10% Normal Goat Serum with 0.2% Triton X-100 in 1X PBS (blocking 
solution) for 1 hour at room temperature.  Primary antibodies were diluted (Table 1) in blocking 
solution; cells were incubated in primary antibodies overnight at 4˚C.  They were then washed in 
D-PBS and incubated in a secondary antibody diluted (Table 1) in the blocking solution for 45 
minutes at room temperature.  After a final series of washes, coverslips were mounted on glass 
slides (Fisher Scientific) using Vectashield with DAPI (Vector Labs).  Fluorescence imaging of 
immunocytochemical staining was performed on an upright Olympus IX71 microscope with a 
Hamamatsu black and white camera and HCImage software (Hamamatsu, Hamamatsu City, 
Japan). Exposure times were set using cells incubated with secondary antibody only and kept 
consistent within experiments. 
 
Image Analysis: The Cell Profiler image analysis software (www.cellprofiler.org) was used to 
measure the mean intensity of the fluorescence signal in the nucleus, the cytoplasmic region, 
and the whole cell [21].  The DAPI image was used to identify the nuclear compartment, from 
which the cytoplasmic region of interest was defined as a pre-set distance of 10 pixels from the 
nuclear border. In primary cell cultures, neurons were identified by their PSD-95 
immunofluorescence under FITC filters. The nuclear outlines of the neuron were overlaid on the 
TXRED image to measure the fluorescence intensity of the protein of interest. Nuclear 
translocation was measured as a change in the ratio between the nuclear and cytoplasmic 
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intensities of GR immunofluorescence, which was then normalized to the nuclear-to-cytoplasmic 
ratio in vehicle-treated cells.   
 
Transfection: Transfection of cell lines was conducted at the time of plating, while cells were in 
suspension, using the Neon® Transfection System (Life Technologies, Grand Island, NY) 
according to the manufacturer’s instructions.  The specific transfection profile for N42 cells was 
1600 mV, 10 ms, 2 pulses for a 100 µL transfection tip, at a density of 2x10-6 cells, which was 
then distributed evenly between 24 wells in a 96-well plate. Cells were co-transfected with 75 ng 
GRE-TK-Luc and 10 ng CMV-Renilla Luciferase (a gift from Dr. Greti Aguilera), and allowed to 
adhere to coverslips overnight.  The media was then changed to N42 medium supplemented 
with 5% CS FBS for 16 hours. Cells were treated with hormone for 20 minutes; the hormones 
were then removed and fresh media was added for 24 hours.  Cells were assayed for luciferase 
activity with the Dual-Glo Luciferase Assay System (Promega, Madison, WI) using a VICTOR 
luminometer and accompanying software (PerkinElmer, Waltham, MA).   
 
GR-GFP transfection and live imaging: Transfection with GFP-tagged GR (a gift from Dr. 
Louis Muglia) was performed as described above. Following transfection, N42 hypothalamic 
cells were plated on 35 mm culture dishes with a No. 0 cover glass bottom, and allowed to 
adhere overnight. The culture media was changed to N42 media supplemented with 5% CS 
FBS 16 hours prior to imaging, which was performed on a Nikon A1+ laser confocal microscope 
(Nikon Instruments Inc, NY). Images were taken every 15 seconds with a 28 µm pinhole size to 
track GR transport from the cytosol to the nucleus. Dex or Dex-BSA was added after 5 minutes 
of baseline imaging. Average intensities within a nuclear region of interest were calculated using 
NIS-Elements analysis software (Nikon Instruments, Inc.), and used to quantify nuclear 
translocation.  
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In-Cell Western: N42 Cells were fixed in 4% paraformaldehyde for 15 minutes at room 
temperature in 96-well plates and then permeabilized with 1X D-PBS with 0.1% Triton X-100.  
The cells were incubated in Odyssey Blocking Buffer (in PBS) (LI-COR Biosystems) for 1 hour 
at room temperature and then incubated in primary antibodies diluted (Table 2) in Odyssey 
Blocking Buffer (PBS) overnight at 4°C with gentle shaking.  The cells were then washed in 1X 
D-PBS with 0.1% Tween20 and incubated in secondary antibody diluted (Table 2) in Odyssey 
Blocking Buffer (PBS) with 0.2% Tween20 for 1 hour at room temperature with gentle shaking.  
Plates were then imaged on an Odyssey CLx Imager (LI-COR Biosciences) and analyzed using 
Image Studio Lite Version 4.0.21 software (LI-COR Biosciences). 
 
Microarray Analysis: For microarray analysis, three array groups were prepared: N42 cells 
were treated for 24 hours with vehicle, Dex (1 µM), or Dex-BSA (100 nM) and were tested with 
three biological replicates for each group. Total RNA from N42 cell cultures was extracted using 
the Aurum™ Total RNA Mini Kit (Bio-Rad, U.S.A). Mouse OneArray® microarray hybridization 
and data analysis were performed on the total RNA samples by Phalanx Biotech Group 
(Phalanx Biotech Group, San Diego, CA). Differentially expressed genes were those with a log2 
(fold change) ≥ 0.5 and a P < 0.05. 
 
In Vivo experiments: Adult male Sprague-Dawley rats (Harlan, Indianapolis, IN) were 
adrenalectomized and implanted with bilateral cannulas aimed at the paraventricular nucleus of 
the hypothalamus (PVN), as previously described [22]. Males were used to match our previous 
electrophysiological studies on rapid glucocorticoid actions in hypothalamic neurons. 
Stereotaxic coordinates were 1.9 mm posterior and 0.5 mm lateral to bregma, with injection 
cannula tips placed 7.3 mm ventral to the dura mater. After cannula implantation, rats were 
allowed to recover for 7 days prior to injections, with access to 0.5 M NaCl and water. They then 
received bilateral 500 nl injections of Dex (25 pg), Dex-BSA (1.25 µg), or vehicle (0.9% saline). 
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Thirty minutes after injections, the rats were killed by sodium pentobarbital overdose and 
perfused with 3.7% formaldehyde. Brains were immersed overnight in 30% sucrose and 
sectioned at 25 µm on a sliding microtome, and sections were stained for fluorescence 
immunohistochemistry. Primary antibodies used were rabbit anti-BSA (Rockland, Limerick, PA) 
at a 1:500 dilution and rabbit anti-GR (M-20, Santa Cruz Biotechnology, Dallas, TX) at a 1:500 
dilution. Images were captured using an LSM 510 confocal microscope (Zeiss, Thornwood, NY). 
 
Statistical Analysis: Data are presented as means ± SEM. All statistical analyses were 
performed using Prism version 5.04 (GraphPad Software, San Diego, CA).  One-way analysis of 
variance (ANOVA) was used to compare three or more groups. Post-hoc multiple comparisons 
were performed using Bonferroni’s analysis in most cases, or Tukey’s analysis when comparing 
all possible combinations of data sets. Two-way ANOVA was used to compare multiple data 
sets over time.  
 
 
RESULTS 
Membrane-initiated glucocorticoid signaling induces GR nuclear translocation 
Nuclear localization of the GR was measured in the N42 hypothalamic cell line following 
exposure to Dex, which crosses the plasma membrane, and to Dex-BSA, which is membrane-
impermeant (Weiss et al., in review). Treatment with Dex and Dex-BSA for 20 minutes resulted 
in a concentration-dependent increase in the nuclear localization of the GR (Fig. 1a).  Both Dex 
and Dex-BSA were sufficient to induce GR nuclear translocation at concentrations greater than 
100 nM, and had similar effective concentrations at 1 µM and 100 nM, respectively. (Fig. 1b).  
Dex treatment resulted in a significant increase in the nuclear localization of the GR within 10 
minutes, while Dex-BSA treatment required 20 minutes to significantly increase GR nuclear 
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localization (Fig. 1c).  GR translocation similar to that observed with Dex and Dex-BSA was also 
seen in response to exposure to the endogenous glucocorticoid corticosterone (1 µM) (data not 
shown). 
To confirm that free Dex is not present in the Dex-BSA solution, we tested the effect of 
media treated with Dex-BSA at 100 nM for 20 minutes under experimental conditions (1X 
DMEM supplemented with 0.5% CS FBS at 37°C and 5% CO2).  Media filtered through a 10 kD 
Amicon filter, which should contain solutes with a mass <10 kD, including free Dex (mw = 
392.461 g/mol), was applied to N42 cells for 20 minutes.  The Dex-BSA filtrate did not induce 
GR nuclear localization (Fig. 2). 
Primary hypothalamic cell cultures from postnatal day 1 C57BL/6 mice were also tested 
for GR nuclear translocation at 7 days in vitro. They were subjected to treatment with DMSO, 
Dex (1 µM), or Dex-BSA (100 nM) for 20 minutes. Neurons in the primary cultures were 
identified by immunostaining for PSD-95, a neuronal marker.  Although GR 
immunofluorescence was localized to the nucleus and cytosol prior to treatment, both Dex and 
Dex-BSA treatments resulted in an increase in GR nuclear localization in these cells (Fig. 3).  
The ability of Dex and Dex-BSA to induce nuclear translocation of the GR was also 
tested in vivo in the PVN of adrenalectomized rats. Dex (25 pg), Dex-BSA (1.25 µg), or saline 
was injected into the PVN of anesthetized rats. Dex and Dex-BSA, but not saline, caused a 
significant increase in the nuclear localization of the GR (Fig. 4A-C). 
To further explore the differences in kinetics seen in GR immunostaining, we transfected 
N42 cells with a GFP-tagged GR and imaged the cultures under the confocal microscope in 
order to track the receptor in real time in living cells. Both Dex (1 µM) and Dex-BSA (100 nM) 
treatments caused nuclear translocation within 5 minutes (Fig. 5A). The relative change in 
nuclear intensities was ~45% lower in Dex-BSA- compared to Dex-treated cells at 5 minutes (p 
< 0.001) (Fig. 5B), but was no longer different at 25 minutes of hormone treatment (p = 0.105). 
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Nonlinear regression confirmed a faster time constant for Dex-induced translocation (τ = 3.583 
min) than for Dex-BSA-induced translocation (τ = 8.206 min). These data suggest that GR 
translocation due to Dex or Dex-BSA reaches a common saturation point, but that Dex-BSA-
induced translocation occurs at a slower rate, consistent with the slower time course of GR 
translocation that we observed using immunostaining in fixed cultures. 
 
Role of intracellular signaling pathways in membrane-initiated GR nuclear translocation 
The difference in the kinetics of Dex- and Dex-BSA-induced GR nuclear translocation 
suggests that GR trafficking initiated by glucocorticoid signaling from the membrane uses a 
different signaling mechanism than that stimulated by intracellular glucocorticoid binding directly 
to the GR. Intracellular glucocorticoid-induced nuclear trafficking of the GR is dependent on the 
GR chaperone HSP90 [23].  To test the dependence of Dex-BSA-mediated GR nuclear 
translocation on HSP90, N42 cells were treated with the HSP90 inhibitor geldanamycin (100 
µM) for 30 minutes prior to a 20-minute hormone treatment.  Both Dex- and Dex-BSA-induced 
GR nuclear translocation were reduced following geldanamycin treatment (Fig. 6), suggesting a 
common dependence of the two signaling pathways on HSP90.  
The membrane-initiated trafficking of an unliganded GR may involve signaling from the 
membrane to the GR via a kinase- or calcium-dependent mechanism. We have reported 
previously that rapid glucocorticoid-induced endocannabinoid release from hypothalamic 
neuroendocrine cells is dependent on G protein, PKA and PKC activities [24,25], as well as on 
ERK-MAP kinase, Src kinase, and intracellular calcium mobilization (unpublished observations). 
Here, we tested for the dependence of the membrane-initiated nuclear translocation on 
intracellular signaling pathways using kinase inhibitors and activators and a calcium chelator.  
We tested the pharmacological inhibition of ERK-MAP kinase with the MEK inhibitor PD 
0325901 (50 nM, Tocris), of PKA with Rp-adenosine 3′,5′-cyclic monophosphorothioate 
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(RpcAMPs) (50 µM, Sigma-Aldrich), of Src with PP2 (50 µM, Sigma-Aldrich), of p38 MAPK with 
SB 202190 (10 µM, Tocris), and of Akt with 10-DEBC‧HCl (5 µM, Tocris), and the inhibition of 
intracellular calcium signaling with the membrane-permeant calcium chelator BAPTA-AM (50 
µM, Sigma-Aldrich). None of these kinase or calcium signaling inhibitors had any effect on the 
Dex- or the Dex-BSA-induced increase in nuclear localization of GR (Fig. 7A). We also tested 
for PKC dependence of the Dex- and Dex-BSA-induced nuclear localization of GR with the PKC 
inhibitor Go6983 (10 µM, Tocris), but the autofluorescence of the inhibitor rendered the 
measurement of the GR immunofluorescence unreliable. We next tested for nuclear 
translocation of GR by pharmacological activation of PKA with 8-bromoadenosine 3′,5′-cyclic 
monophosphate (8-Br-cAMP, 10 nM, Sigma-Aldrich), of p38 MAPK with anisomycin (10 µM, 
Sigma-Aldrich), and of Akt with SC79 (11 µM, Tocris), each of which failed to increase GR 
nuclear localization at the concentrations tested (data not shown). Finally, we tested the PKA, 
p38 MAPK, and Akt activators at the same concentrations in combination with Dex (1 µM) and 
Dex-BSA (100 nM); the PKA and p38 MAPK activators, 8-Br-cAMP and anisomycin, had no 
effect on the Dex- and Dex-BSA-induced increase in GR nuclear localization.  Interestingly, 
however, the Akt activator SC79 (11 µM) blocked the Dex-BSA-induced, but not the Dex-
induced, increase in GR nuclear localization (Fig. 7B, C). 
In-cell westerns for phosphorylated ERK 1/2, Akt, and p38 MAPK were also performed 
on N42 cells treated with Dex or Dex-BSA for 10, 20, 30, 45, and 60 minutes to determine 
whether the glucocorticoids activated these kinases. There was no difference in the 
phosphorylation of any of the kinases tested at any of the time points (Fig.8). 
  
Transcriptional regulation by Dex and Dex-BSA 
We used a GRE-luciferase assay to determine the GRE-dependent transcriptional 
activity of Dex and Dex-BSA in the N42 cells. Dex (1 µM) or Dex-BSA (100 nM) was applied to 
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cultures for 20 minutes and luciferase activity was measured to monitor GRE activation 24 
hours later. The Dex exposure caused a robust increase, whereas the same exposure to Dex-
BSA failed to cause a significant increase in luciferase activity (Fig. 9A).   
The differential GRE activation observed with the GRE-luciferase assay suggested that 
the liganded and unliganded GR regulate gene transcription differently. We performed a 
preliminary microarray analysis on N42 cells to test this hypothesis. N42 cell cultures were 
treated with either Dex (1 µM) or Dex-BSA (100 nM) for 24 hours.  As expected, 24 hours of 
Dex treatment resulted in the up- or down-regulation of more than 400 genes (Fig. 9B). Dex-
BSA treatment also resulted in the regulation of hundreds of genes, although most of these 
were uniquely regulated by the Dex-BSA treatment and not by the Dex treatment (Fig. 9B), 
suggesting the differential transcriptional regulation by the unliganded GR compared to the 
liganded GR. 
 
DISCUSSION 
The main finding of this study is that glucocorticoid signaling from the membrane can 
induce the nuclear translocation of the GR, which suggests trafficking of an unliganded GR that 
is activated by glucocorticoid binding to a membrane-associated receptor.  Corticosterone also 
caused GR nuclear translocation, indicating that the synthetic steroids acted in a similar manner 
as the endogenous steroid.  The similar response observed in primary hypothalamic cell 
cultures in vitro and following steroid injection into the PVN in vivo provided evidence that the 
Dex- and Dex-BSA-induced nuclear translocation of GR observed in the N42 hypothalamic cell 
line also occurs in native hypothalamic neurons. 
The Dex-BSA-induced GR translocation was slower than the Dex-induced GR 
translocation, which could provide insight into mechanisms of unliganded GR trafficking. For 
example, time might be required following glucocorticoid binding to the membrane for the GR to 
move to the membrane [26] to be exposed to the steroid signal. Thus, the GR may need to be 
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trafficked to the membrane in order to receive a membrane-restricted signal, either from the 
ligand directly or from a nearby membrane receptor. Although not studied directly, we saw no 
evidence for trafficking of the GR to the membrane following glucocorticoid application. The Dex 
group of the Dex-BSA conjugate is not long enough to protrude through the plasma membrane 
lipid bilayer, so it would be necessary for some portion of the GR to enter the membrane in 
order for Dex-BSA to directly interact with the GR. Alternatively, Dex-BSA could bind to an 
unidentified membrane receptor, which could then relay a signal to the GR to trigger 
translocation. Either process may be slower than free Dex diffusing into the cell and binding to 
the GR. Another possible explanation for the difference in kinetics between the two steroids is 
that the number of Dex molecules in the Dex-BSA conjugate available to bind to the membrane 
receptor (the Dex-to-BSA ratio in the Dex-BSA conjugate was 37-to-1) was fewer than in the 1-
µM Dex solution, which may have slowed the binding reaction. 
The trafficking of an unliganded GR by glucocorticoid actions at the membrane 
implicates the activation of a membrane receptor-initiated signaling mechanism. We found 
previously in ex-vivo brain slices that rapid glucocorticoid actions in hypothalamic neurons and 
neurons of the basolateral amygdala are dependent on G protein-coupled receptor and protein 
kinase activation [24,25,27,28]. Other studies have demonstrated that glucocorticoids can 
rapidly activate multiple kinase pathways in cultured cells, including both serine/threonine 
kinase and tyrosine kinase signaling pathways [29].  For example, glucocorticoids activate ERK 
1/2 within 1 hour in an anterior pituitary cell line [30], and rapidly inhibit calcium influx into HT4 
and PC12 cells via PKA and PKC activation, respectively [16].  In primary hippocampal neurons, 
glucocorticoids activate JNK and p38 MAP kinases [18], and inhibition of GR results in the 
reduction of Akt and ERK phosphorylation within 30 minutes [31]. In contrast to studies of other 
forms of rapid glucocorticoid signaling that showed kinase dependence (23-28), we did not find 
that the GR nuclear translocation induced by membrane glucocorticoid signaling was dependent 
on, or was activated by, any of a battery of kinases. It is possible that we missed inhibitory or 
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activational effects of drugs tested at a single concentration, however, the concentrations of the 
kinase activators and inhibitors that we employed in these experiments have been 
demonstrated to be effective in other studies. The lack of kinase involvement in GR nuclear 
translocation suggests that either the membrane receptor or the signaling cascades engaged by 
the membrane receptor may be different for distinct rapid glucocorticoid actions. 
Post-translational modifications of the GR can alter the transcriptional effects of GR 
activation [32], and may provide a mechanism for the interactions between cell signaling 
pathways and GR-mediated transcriptional activity.  Dex-BSA treatment reportedly increased 
p38 MAPK activation in CD14-positive monocytes [19], and both pharmacological and siRNA-
mediated inhibition of p38 MAPK increased GR nuclear localization [33], presenting the 
possibility that Dex-BSA-induced p38 activation could inhibit GR nuclear localization  Consistent 
with this, GR phosphorylated at serine 232, a putative p38 MAPK site, was less transcriptionally 
active in rat primary cortical neuron cultures [34].  However, in leukemia cell lines [35] and in 
osteosarcoma and lung cancer cell lines [36],  p38 MAPK phosphorylation of the GR at serine 
211 (pGR S211, which is orthologous to serine 232 in the rat) increased GRE-mediated 
transcription, suggesting that the effects of phosphorylation are cell-type specific [37].   
We did not find evidence for the induction of GR trafficking by the activation of any of 
several kinases or by calcium. Thus, we found no effect on GR nuclear translocation by 
activating PKA, Akt, MEK, p38 MAPK, or Src, and no effect on the Dex- or Dex-BSA-induced 
GR trafficking by inhibition of PKA, Akt, MEK, p38 MAPK, or Src, or by blocking intracellular 
calcium signaling. Similarly, we did not find evidence of phosphorylation or activation of PKA, 
Akt, MEK, p38 MAPK, or Src by Dex or Dex-BSA with an in-cell Western blot assay. While we 
tested for the dependence of glucocorticoid-induced GR trafficking on a battery of kinases, this 
list of kinases was not exhaustive, and only one concentration of the different kinase activators 
and inhibitors was tested, albeit a commonly used concentration. We did not test, for example, 
the dependence of GR translocation on PKC activity, as the PKC analogs we tested were 
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autofluorescent, which interfered with the nuclear localization analysis. Thus, we cannot exclude 
the possibility that a kinase is responsible for signaling from the membrane to the intracellular 
GR to induce the translocation of the GR to the nucleus. Nevertheless, this raises the alternative 
possibility that the nuclear translocation of the unliganded GR is not kinase dependent and may 
be due either to a direct interaction of the GR with the membrane-restricted steroid or to another 
post-translational modification of the GR.  
We found that Akt activation inhibited the nuclear translocation of GR induced by Dex-
BSA, but not by Dex. Akt is part of the PI3 kinase signaling pathway, which can be activated at 
the plasma membrane by receptor tyrosine kinases and G-protein coupled receptors that 
respond to growth factors and cytokines [38].  Rapid Akt phosphorylation in response to 
glucocorticoids has been reported in human epithelial cells in the presence of a transcription 
inhibitor [39].  We were not able to detect any change in Akt phosphorylation in response to Dex 
or Dex-BSA treatment or an effect of Akt activation on Dex-mediated GR nuclear localization, 
which suggests that membrane glucocorticoid signaling may be regulated by the intracellular 
environment.  Under conditions in which the PI3K pathway is active, such as in response to 
insulin exposure [40], hypothalamic neurons may respond differently to glucocorticoids.   
The nuclear translocation of the GR by both Dex and Dex-BSA was blocked following 
inhibition of Hsp90.  This suggests that the chaperone complex, of which HSP90 is a 
component and which traditionally retains the GR in the cytoplasm in the absence of ligand 
binding, is required for the successful nuclear transport of both the liganded and unliganded 
receptor.  
The identity of the membrane receptor responsible for signaling to the GR is not known.  
GR immunoreactivity has been detected in the membrane in lymphoma [41] and breast cancer 
(MCF-7) cell lines [42], in transfected HEK 293T cells [19], in pituitary cell lines [26], and in 
native hypothalamic neuroendocrine cells [43], suggesting that the GR itself, or an isoform of 
the GR, may be the membrane receptor. The GR has also been detected in neuronal 
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membranes in some studies using immunocytochemistry and electron microscopy [44,45], while 
other studies have suggested that standard immunocytochemical methods are not sensitive 
enough to detect low levels of GR in the plasma membrane [42]. Glucocorticoids bind to 
neuronal membranes with ~10-fold lower affinity than in the cytosol, suggesting that the 
membrane receptor is significantly lower in abundance than the cytosolic receptor [43,46], which 
may account for the difficulty of detection of the GR in the membrane. On the other hand, rapid 
actions via a membrane receptor have been shown in several, though not all, studies to have a 
different pharmacology than the intracellular GR (i.e., they are insensitive to the GR antagonist 
RU486) [24,28] and to be blocked by inhibiting G protein activity [25], which suggests that the 
membrane receptor may be distinct from the classical GR. 
Dex treatment resulted in the expected activation of the GRE, and regulated the 
transcription of hundreds of genes in the N42 cell line.  Although Dex-BSA did not significantly 
regulate transcription via the GRE based on our GRE-luciferase assay, our microarray results 
indicated that the unliganded GR is nevertheless capable of transcriptional regulation.  Thus, 
multiple genes were upregulated and over two hundred genes were down-regulated in response 
to Dex-BSA treatment in N42 cells.  Some of these genes may have been regulated in response 
to intracellular signaling pathways activated by Dex-BSA, but it is likely that the unliganded GR 
also regulated transcription following translocation to the nucleus. Interestingly, there was 
relatively little overlap between the genes regulated by Dex and those regulated by Dex-BSA, 
suggesting differential transcriptional regulation by the liganded and unliganded GR.  These 
preliminary findings support the need for further investigation into the potential for membrane-
initiated transcriptional regulation by the unliganded GR. 
In conclusion, membrane-restricted Dex-BSA induced the nuclear translocation of GR in 
hypothalamic neurons to a degree that was comparable to that elicited by Dex, albeit with 
slower kinetics.  Because free Dex does not dissociate from the Dex-BSA this suggests that 
glucocorticoid signaling from the membrane is capable of inducing the nuclear translocation of 
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the unliganded GR. The molecular mechanism for this membrane-initiated trafficking of the 
unliganded GR is not known, although it appears to be independent of PKA, Akt, MEK, p38 
MAPK, Src and calcium signaling, and it is blocked by Akt activation.  Nuclear translocation is 
part of the classical GR signaling pathway, and is necessary for GRE regulation of transcription; 
however, we demonstrate here that non-classical glucocorticoid signaling via a membrane GR 
induces the nuclear translocation of an unliganded GR and subsequent transcriptional 
regulation that appears to be independent of activation of the GRE.  This divergence in the 
transcriptional signaling of the unliganded and liganded GR may represent a mechanism for 
finely controlling transcriptional output by glucocorticoids under different physiological and/or 
cellular conditions.  
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Figure Legends 
Figure 1. Nuclear translocation of the GR by Dex and Dex-BSA. A) GR Immunofluorescence in 
N42 cells in control media (No Treatment) and media containing Dex and Dex-BSA. Nuclear 
localization of GR was seen following a 20-min treatment with Dex (10-6 M) and Dex-BSA (10-7 
M). B) Dose-dependence of GR nuclear localization following a 20-min treatment with Dex and 
Dex-BSA. C) Time-course of GR nuclear localization with Dex and Dex-BSA. Dex achieved a 
maximal nuclear localization of GR within 10 min, whereas the Dex-BSA-mediated increase in 
GR nuclear localization reached a maximum at 20 min. Both persisted for over 90 min. **p < 
0.01, two-way ANOVA. 
 
Figure 2. Absence of free Dex in Dex-BSA preparation.  Dex-BSA (100 nM) was maintained in 
solution at 37°C for 20 minutes, and was then filtered through a 10 kD Amicon filter (Millipore).  
Dex and Dex-BSA treatment induced an increase in the ratio of Nuclear-to-cytoplasmic GR 
immunofluorescence (Nuc : Cyto Intensity), but the Dex-BSA filtrate had no effect on GR 
localization. *, p < 0.05, **, p < 0.01 compared to vehicle or as indicated, one-way ANOVA with 
Tukey’s’s post hoc test. 
 
Figure 3. Dex and Dex-BSA induce GR nuclear translocation in primary hypothalamic neurons. 
A) Representative images of GR immunofluorescence in primary hypothalamic neuronal 
cultures. Lower panel: Colorized images of GR immunofluorescence (red) in PSD-95-positive 
neurons (green) and DAPI nuclear stain (blue). Upper panel: High-magnification images of GR-
positive neurons (yellow outline) from images below (arrows). Dex and Dex-BSA treatment for 
20 min increased the nuclear staining and decreased the cytoplasmic staining for GR.  B) Ratio 
of nuclear : cytoplasmic staining of GR. Data represent average nuclear : cytoplasmic GR 
immunofluorescence of individual neurons identified by PSD-95 staining (DMSO n=13, Dex n=9, 
Dex-BSA n=11). **, p<0.01, one-way ANOVA with Tukey’s post hoc test compared to DMSO. 
  
  
 
Figure 4. Dex and Dex-BSA induce nuclear translocation of the GR in vivo. Glucocorticoid 
immunofluorescence in sections of the PVN from adrenalectomized adult male rat brains 
following in-vivo delivery into the PVN of vehicle (A), Dex (B), or Dex-BSA (C). Nuclear 
localization of the GR was seen after intra-PVN injection of Dex and Dex-BSA, but not vehicle. 
Images were taken under a 20x objective and a 63x objective (insets). 3V, third ventricle. Scale 
bar in inset in A also applies to insets in B and C. 
 
Figure 5. Live-cell imaging of Dex- and Dex-BSA-induced nuclear translocation of GFP-labeled 
GR. A. Cells transfected with GR-GFP were imaged during application of Dex or Dex-BSA. 
Progressive GR-GFP nuclear translocation can be seen at 5 minutes and 25 minutes of steroid 
application. B. Nuclear fluorescence intensity normalized to baseline revealed a time-dependent 
increase in GFP intensity in the nucleus, which was more rapid with Dex application than with 
Dex-BSA application. Dex caused significantly more nuclear translocation than Dex-BSA at 5 
minutes (p<0.001), but not at 25 minutes (p=0.105) of steroid application, one-way ANOVA with 
Bonferroni post hoc test. 
 
Figure 6. HSP90 is required for Dex- and Dex-BSA-induced GR nuclear translocation. Nuclear : 
cytoplasmic intensity of GR after a 20-min exposure to Dex or Dex-BSA was increased 
compared to vehicle (DMSO), but was not significantly different from vehicle in N42 cells pre-
treated for 15 min with the HSP90 inhibitor geldanamycin (Geld), compared to vehicle (DMSO + 
Geld), *, p < 0.05; **, p < 0.01, one-way ANOVA with Bonferroni post hoc test. Data represent 
the average of at least 3 independent experiments. 
 
  
  
Figure 7. Effect of kinase or intracellular calcium manipulation on GR nuclear translocation. A. 
GR nuclear localization by Dex and Dex-BSA was not significantly different from vehicle in N42 
cells treated for 15 min with the following inhibitors: the MEK inhibitor PD 302591 (PD),  PKA 
inhibitor RpcAMPs (RpcAMP), Src inhibitor PP2, p38 MAPK inhibitor SB 202190 (SB), Akt 
inhibitor 10-DEBC‧HCl (DEBC), and the membrane-permeant calcium chelator BAPTA-AM 
(BAPTA). B. Akt activation with SC79 inhibited the Dex-BSA-induced GR nuclear localization in 
N42 cells. GR immunofluorescence is shown in red. C. Quantification of the intensity of the 
nuclear : cytoplasmic ratio in the presence and absence of the Akt activator SC79. SC79 had no 
effect on the increase in the nuclear : cytoplasmic GR ratio induced by Dex. However, the 
nuclear : cytoplasmic ratio following Dex-BSA treatment in the presence of SC79 was 
significantly less than following Dex-BSA treatment alone and did not differ from vehicle 
treatment. Data represent the mean of 3-13 independent experiments. *, p < 0.05, one-way 
ANOVA with Bonferroni post hoc test. 
 
Figure 8. ERK, Akt and p38 MAPK activation do not change with Dex or Dex-BSA treatment.  
N42 cells were treated with vehicle for 60 minutes, or Dex or Dex-BSA for 10, 20, 30, 45, or 60 
minutes.  In-cell Westerns for A) phosphorylated ERK (T202/Y204)/total ERK (pERK/ERK), B) 
phosphorylated Akt (S473)/total Akt (pAkt/Akt), or C) phosphorylated p38 MAPK 
(T180/Y182)/total p38 MAPK (pp38MAPK/p38MAPK) were performed using the Odyssey 
system.  There was no significant difference between Dex or Dex-BSA treatment and vehicle at 
any of the time points (p > 0.05, 2-way ANOVA). 
 
Figure 9. Differential transcriptional effects of Dex and Dex-BSA. A. N42 cells transfected with 
GRE-TK-Luciferase for 24 hours were treated with Dex or Dex-BSA for 20 min.  Hormone was 
  
  
removed and replaced with fresh media for 24 hours before lysis. **, p < 0.01; ns, p=0.064 
compared to vehicle, two-tailed t-test; vehicles: DMSO and cyclodextrin in water (CD). B. Venn 
diagram for gene expression profiles in N42 cells following 24 hours of Dex and Dex-BSA 
treatment, from a Mouse OneArray® microarray (Phalanx Biotech Group) on 3 independent 
biological replicates.  Genes reported show a ≥ 0.5-fold difference in expression (p < 0.05) 
compared to vehicle-treated cells. 
  
  
  
  
  
  
  
  
  
  
  
  
Table 1. Antibody Dilutions (N42 and primary hypothalamic cell cultures) 
Antibody Name/Target Source Host Species Dilution 
GR (M-20) Santa Cruz Biotechnology, Inc.  Rabbit 1:300 
PSD-95 NeuroMab Mouse 1:1000 
Goat anti-Rabbit IgG (H+L) 
Secondary Antibody, Dylight 594 
conjugate 
Thermo Fisher 
Scientific Goat 1:750 
Goat anti-Mouse IgG (H+L) 
Secondary Antibody, Dylight 488 
conjugate 
Thermo Fisher 
Scientific Goat 1:750 
 
 
  
  
  
Table 2. Antibody Dilutions for In-Cell Westerns™ 
Antibody Name/Target Source Host Species Dilution 
anti-PhosphoT202/Y204 ERK Phosphosolutions® Rabbit 1:100 
pan ERK BD Biosciences San Jose, CA Mouse 1:300 
Phospho-Akt (Ser473) 
(D9W9U) 
Cell Signaling Technology® Mouse 1:100 
Akt Antibody Cell Signaling Technology® Rabbit 1:200 
Phospho-p38 MAPK 
(Thr180/Tyr182) (D3F9) 
XP®  
Cell Signaling Technology® 
Rabbit 1:800 
P38α/β (A-12) Santa Cruz Biotechnology, Inc. Mouse 1:100 
IRDye 680RD Goat anti-
Mouse IgG 
LI-COR Biosystems Goat 1:800 
IRDye 800CW Goat anti-
Rabbit IgG 
LI-COR Biosystems 
 
Goat 1:800 
 
 
 
 
